CBIO Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
3.1M
0
-100.0%
1.0M
-90.4%
10.8M
0
Cost of Revenue
0
0
0
0
0
Gross Profit
3.1M
0
-100.0%
1.0M
-90.4%
10.8M
0
Operating Expenses
43.0M
+63.2%
26.4M
+2.3%
25.8M
-74.8%
102.3M
+295.3%
25.9M
R&D
34.3M
+76.9%
19.4M
+8.3%
17.9M
-81.2%
95.0M
+367.0%
20.3M
SG&A
8.7M
-0.3%
8.7M
+11.2%
7.9M
+7.6%
7.3M
+32.0%
5.5M
Operating Income
-39907000
-51.4%
-26364000
-6.6%
-24729000
+73.0%
-91492000
-253.5%
-25885000
EBITDA
-39840000
-51.5%
-26298000
-6.6%
-24665000
+73.0%
-91438000
-253.6%
-25857000
Net Income
-37726000
-51.9%
-24837000
-6.7%
-23283000
+74.8%
-92397000
-275.5%
-24607000
EPS (Basic)
$-0.90
-21.6%
$-0.74
-5.7%
$-0.70
+82.3%
$-3.96
-211.8%
$-1.27
EPS (Diluted)
$-0.90
-21.6%
$-0.74
-5.7%
$-0.70
+82.3%
$-3.96
-211.8%
$-1.27
Shares (Diluted)
39.1M
+27.9%
30.5M
+0.4%
30.4M
+48.4%
20.5M
+23.8%
16.5M
Crescent Biopharma (CBIO) — Financials